Strategic integration of in vivo cardiovascular models during lead optimization: Predictive value of 4 models independent of species, route of administration, and influence of anesthesia

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 4, 2012, Pages 369-376

  Fryer, Ryan M ^a   Harrison, Paul C ^a   Muthukumarana, Akalushi ^a   Nodop Mazurek, Suzanne G ^a   Ng, Khing Jow ^a   Chen, Rong Rhonda ^a   Harrington, Kyle E ^a   Dinallo, Roger M ^a   Chi, Liguo ^a   Reinhart, Glenn A ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

anesthetized; dog; drug discovery; hemodynamics; in vivo; lead optimization; rat; telemetry; torcetrapib

Indexed keywords

SHM 1121X; STEROID HORMONE; TORCETRAPIB; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOEQUIVALENCE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; HEMODYNAMICS; HYPOTENSION; IN VIVO STUDY; LOW DRUG DOSE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PHARMACODYNAMICS; PREDICTIVE VALIDITY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SUSPENSION; TELEMETRY; THEORETICAL MODEL;

ADMINISTRATION, ORAL; ANESTHESIA; ANIMALS; ANTICHOLESTEREMIC AGENTS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; INFUSIONS, INTRAVENOUS; MALE; MODELS, ANIMAL; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY;

EID: 84859887913     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31824485dd     Document Type: Article

References (34)

1. Stevens JL, Baker TK. The future of drug safety testing: expanding the view and narrowing the focus. Drug Discov Today. 2009;14:162-167.
2. Kurtz TW, Griffin KA, Bidani AK, et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 2: blood pressure measurement in experimental animals: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45:299-310. (Pubitemid 40179976)
3. Polakowski JS, King AJ, Campbell TJ, et al. Cardiovascular effects of torcetrapib in conscious and pentobarbital-anesthetized dogs. J Cardiovasc Pharmacol. 2009;54:543-551.
4. Kym PR, Souers AJ, Campbell TJ, et al. Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists. J Med Chem. 2006;49:2339-2352.
5. Franklin PH, Banfor PN, Tapang P, et al. Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl) phenyl)- N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growth inhibition. J Pharmacol Exp Ther. 2009;329:928-937.
6. Banfor PN, Franklin PA, Segreti JA, et al. ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats. J Cardiovasc Pharmacol. 2009;53:173-178.
7. Honore P, Chandran P, Hernandez G, et al. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Pain. 2009;142:27-35.
8. Prakash C, Chen W, Rossulek M, et al. Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance. Drug Metab Dispos. 2008;36:2064-2079.
9. Banfor PN, Preusser LC, Campbell TJ, et al. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs. Am J Physiol Heart Circ Physiol. 2008;294:H238-H248.
10. Fryer RM, Preusser LC, Calzadilla SV, et al. (2)-(9S)-9-(3-Bromo-4- fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quin olin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine. J Cardiovasc Pharmacol. 2004;44:137-147. (Pubitemid 38982155)
11. Fryer RM, Rakestraw PA, Preusser LC, et al. Pharmacological characterization of the novel dihydropyridine potassium channel opener, (9R)-9- (3-iodo-4-methylphenyl)-5,9-dihydro-3H-furo[3,4-b]pyrano[4,3-e]pyridine-1,8 (4H,7H)-dione (A-325100), and the regulation of cardiovascular function in conscious and anesthetized beagle dogs. J Cardiovasc Pharmacol. 2005;46:232-240. (Pubitemid 41060217)
12. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122. (Pubitemid 350146106)
13. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intimamedia thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet. 2007;370:153-160. (Pubitemid 47042895)
14. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med. 2007;356:1620-1630. (Pubitemid 46631671)
15. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356:1304-1316. (Pubitemid 46513296)
16. Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol. 2008; 154:1465-1473.
17. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363: 2406-2415.
18. Horowitz JD, Rosenson RS, McMurray JJ, et al. Clinical Trials Update AHA Congress 2010. Cardiovasc Drugs Ther. 2011;25:69-76.
19. Betageri R, Gilmore TA, Harcken CHJJ, et al. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof. US Patent 6,903,215 B2. June 7, 2005.
20. Guidance for Industry. S7A Safety Pharmacology Studies for Human Pharmaceuticals. US Department of Health and Human Services, Food and Drug Administration, and Center for Drug Evaluation and Research. 2001.
21. Dampney RA, Blessing WW, Tan E. Origin of tonic GABAergic inputs to vasopressor neurons in the subretrofacial nucleus of the rabbit. J Auton Nerv Syst. 1988;24:227-239.
22. James MA, Robinson TG, Panerai RB, Potter JF. Arterial baroreceptor- cardiac reflex sensitivity in the elderly. Hypertension. 1996;28: 953-960. (Pubitemid 26415810)
23. Milic M, Sun P, Liu F, et al. A comparison of pharmacologic and spontaneous baroreflex methods in aging and hypertension. J Hypertens. 2009;27:1243-1251.
24. Broadley AJ, Frenneaux MP, Moskvina V, et al. Baroreflex sensitivity is reduced in depression. Psychosom Med. 2005;67:648-651. (Pubitemid 41033598)
25. Aydemir M, Yazisiz V, Basarici I, et al. Cardiac autonomic profile in rheumatoid arthritis and systemic lupus erythematosus. Lupus. 2010;19: 255-261.
26. Frattola A, Parati G, Gamba P, et al. Time and frequency domain estimates of spontaneous baroreflex sensitivity provide early detection of autonomic dysfunction in diabetes mellitus. Diabetologia. 1997;40:1470-1475. (Pubitemid 28004942)
27. Weston PJ, Panerai RB, McCullough A, et al. Assessment of baroreceptor- cardiac reflex sensitivity using time domain analysis in patients with IDDM and the relation to left ventricular mass index. Diabetologia. 1996;39:1385-1391. (Pubitemid 26356071)
28. Sugiyama A, Satoh Y, Hashimoto K. In vivo canine model comparison of cardiohemodynamic and electrophysiological effects of a new antipsychotic drug aripiprazole (OPC-14597) to haloperidol. Toxicol Appl Pharmacol. 2001;173:120-128. (Pubitemid 32525712)
29. Atlee JL III, Hamann SR, Brownlee SW, et al. Conscious state comparisons of the effects of the inhalation anesthetics and diltiazem, nifedipine, or verapamil on specialized atrioventricular conduction times in spontaneously beating dog hearts. Anesthesiology. 1988; 68:519-528.
30. Fryer R, Preusser L, Cox B, et al. Hemodynamic and electrocardiographic comparison of the atypical antipsychotic drugs aripiprazole and olanzapine, and the classical antipsychotic, haloperidol, in the anesthetized canine. FASEB J. 2005;18:87 14.
31. Lynch JK, Freeman JC, Judd AS, et al. Optimization of chromone- 2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety. J Med Chem. 2006;49:6569-6584. (Pubitemid 44657451)
32. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 2004;24:490-497. (Pubitemid 38326143)
33. Davidson MH, McKenney JM, Shear CL, et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol. 2006;48:1774-1781. (Pubitemid 44648633)
34. McKenney JM, Davidson MH, Shear CL, et al. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol. 2006;48:1782-1790. (Pubitemid 44648632)